With online health and wellness company Hims & Hers opening a new front in the GLP-1 compounding showdown Thursday, the ...

After a brief delay last month, another piece of the Trump administration’s healthcare policy is falling into place. | On ...

Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees ...

The campaign highlights the crossover that Lilly sees between its own 150 years of working toward scientific progress and the ...

Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. | Amgen added ...

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind ...

Amid the fast-moving rollout of the Wegovy pill, Novo Nordisk has taken to advertising’s biggest stage to help get the word ...

On the branded side of things, Sun’s skin cancer offerings include Odomzo for basal cell carcinoma and Unloxcyt, an ...

Merz Therapeutics has launched a punchy marketing campaign for Parkinson’s disease drug Inbrija, working Muhammad Ali quotes ...

The stock price of BridgeBio plunged 15% Thursday as Pfizer’s reported decision to withdraw a tafamidis patent in the European Union triggered fears of earlier generic entry in the blockbuster ...

Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising ...

After Novo Nordisk projected yesterday that its revenue could decline by as much as 13% in 2026, its share price has ...